Welcome to our dedicated page for Io Biotech SEC filings (Ticker: IOBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IO Biotech, Inc. (Nasdaq: IOBT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed with the Securities and Exchange Commission. IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform, with its lead candidate Cylembio® (IO102-IO103) in advanced clinical development.
Through these filings, investors can review material event disclosures related to IO Biotech’s business. Recent Form 8-K reports describe topline and detailed results from the pivotal Phase 3 IOB-013/KN-D18 trial of Cylembio plus KEYTRUDA® (pembrolizumab) in advanced melanoma, updates on regulatory interactions with the U.S. Food and Drug Administration, and the company’s plans to design a potential new registrational study. Other 8-K filings outline financial results for quarterly periods, restructuring and workforce reduction plans, unregistered sales of equity securities tied to a European Investment Bank loan facility, and changes in executive roles and compensation arrangements.
Stock Titan’s interface is designed to surface key elements of IO Biotech’s filings, such as clinical and regulatory milestones, cash runway commentary, term loan and warrant terms, and board or management actions, while linking back to the full EDGAR documents for detailed review. Users can also monitor securities registration information confirming that IO Biotech’s common stock, par value $0.001 per share, is listed on The Nasdaq Stock Market LLC under the symbol IOBT.
In addition to current reports, investors may use this page to track how IO Biotech describes the status of its Cylembio development program, its broader T-win platform pipeline, and its capital resources over time. AI-powered tools on Stock Titan help summarize complex sections of filings, making it easier to interpret disclosures about clinical trial outcomes, regulatory feedback, financing transactions, and corporate restructuring measures.
IO Biotech, Inc. reported that its board approved a major restructuring and workforce reduction plan to conserve capital and focus on developing Cylembio. The plan will cut approximately 50% of the company’s global workforce.
The company expects to record one-time charges of about $1.0 million to $1.5 million, mainly for severance, continued healthcare, earned vacation and related termination costs, largely in the third quarter of 2025, with payments expected to be completed by the fourth quarter of 2025.
IO Biotech also disclosed that the FDA has recommended it not submit a BLA based on data from the IOB-013 clinical trial, which showed improved progression-free survival for Cylembio plus pembrolizumab but narrowly missed statistical significance. The company plans further discussions with the FDA and European regulators on an additional potential registrational study and possible paths to approval in the United States and European Union.
Amendment No. 7 to Schedule 13D reports that on August 11, 2025 Novo Holdings A/S sold 841,996 shares of IO Biotech common stock at $1.7673 per share in a block trade. After the transaction Novo Holdings beneficially owns 2,512,453 shares and 2,469,135 shares issuable upon exercise of immediately exercisable warrants, which together represent approximately 7.3% of IO Biotech's common stock on a fully counted basis using 65,880,914 outstanding shares. The filing updates the reporting schedule originally submitted in 2021 and confirms Novo Holdings' sole voting and dispositive power over its shares.
IO Biotech reported mixed clinical and financing developments in its Form 10-Q. In a global Phase 3 trial of Cylembio (IO102-IO103) plus pembrolizumab versus pembrolizumab alone in first-line advanced melanoma (407 patients), the combination achieved a median progression-free survival of 19.4 months versus 11.0 months for pembrolizumab alone, with a hazard ratio of 0.77 [95% CI: 0.58-1.00; p=0.056], narrowly missing the pre-specified threshold for statistical significance. An early trend toward improved overall survival was observed (HR 0.79) with results expected to mature in the next six to nine months.
On funding, the company completed a private placement that generated $71.9 million net proceeds and has drawn Tranche A (2.5 million? note: Tranche A funded .0 million) and Tranche B (.5 million) under an EIB loan facility; Tranche C of up to .0 million (.0 million.0? see notes) remains subject to conditions including raising an additional $50.0 million and regulatory milestones. The company disclosed substantial doubt about its ability to continue as a going concern and that additional funding will be required. Earlier clinical data cited include a Phase 1/2 trial with confirmed ORR 73%, CRR 50% and median PFS 25.5 months. IO112 IND filing is anticipated in 2026.
IO Biotech, Inc. filed a current report to note that it has released its financial results for the fiscal quarter ended June 30, 2025. The company issued a press release on August 14, 2025 sharing quarterly results and providing an update on its operations for the same period.
The press release is included as Exhibit 99.1 and is being furnished rather than filed, which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.
IO Biotech disclosed topline results from its Phase 3 IOB-013 study evaluating Cylembio plus pembrolizumab versus pembrolizumab alone as first-line treatment for unresectable or metastatic melanoma. The randomized trial enrolled 407 patients (203 combination, 204 monotherapy). The primary endpoint, progression-free survival assessed by blinded independent review per RECIST v1.1, showed early and sustained separation with a hazard ratio (HR) of 0.77 (95% CI: 0.58–1.00; p=0.056), and median PFS of 19.4 months versus 11.0 months. The primary result falls short of the prespecified significance threshold.
Notable subgroup findings include a pronounced benefit in PD-L1 negative tumors (HR 0.54; mPFS 16.6 vs 3.0 months; nominal p=0.006) and in patients without prior anti–PD-1 therapy (post hoc HR 0.74; mPFS 24.8 vs 11.0 months; nominal p=0.037). Overall survival trends were favorable but immature (HR 0.79; 95% CI: 0.57–1.10). The combination was generally well tolerated; injection site reactions were most common (reported in 56% of combination arm patients) and resolved on treatment. The company plans regulatory discussions about a potential BLA and will present more detailed data. It disclosed an estimated cash balance of approximately $28.1 million plus a €12.5 million tranche drawn under a term loan, which it expects to fund operations into the first quarter of 2026, subject to final close procedures.
IO Biotech (Nasdaq: IOBT) filed an 8-K announcing that it has met the conditions to draw the €12.5 million Tranche B of its previously disclosed €57.5 million term-loan facility with the European Investment Bank (EIB).
In exchange, the EIB received a warrant to purchase up to 4,221,867 shares of common stock at a strike price of $1.3159. The drawdown is expected on or about July 4, 2025.
- The warrant and the underlying shares were issued in a private placement relying on Section 4(a)(2).
- Key warrant terms are unchanged from the December 20 2024 filing.
The transaction bolsters near-term liquidity but introduces potential dilution for existing shareholders.
IO Biotech, Inc. (Nasdaq: IOBT) filed a Form 8-K to disclose an Addendum to the 2017 service agreement with Chief Executive Officer Mai-Britt Zocca, Ph.D. The addendum, executed 19 June 2025 by subsidiary IO Biotech ApS, formalises severance and change-in-control protections.
Standard Qualifying Termination (without cause or by the CEO for good reason) entitles the CEO to:
- Cash severance equal to 12 months of current base salary.
- Pro-rated annual bonus for the year of termination, calculated on actual performance.
- Any unpaid prior-year bonus.
- Accelerated vesting of equity awards scheduled to vest within 12 months after termination, with performance awards vesting on actual results.
Change-in-Control (CIC) Protection: If a Qualifying Termination occurs within six months before or 12 months after a CIC, (i) cash severance increases to 18 months of base salary, (ii) the current-year bonus is paid at full, non-prorated value, and (iii) 100 % of outstanding equity vests immediately, with performance goals deemed met at target or as otherwise specified in award agreements.
All payments are contingent on execution and non-revocation of a general release of claims. The company attached the Addendum as Exhibit 10.1; no other financial statements or exhibits were included.
The disclosure does not alter current operations or financial guidance but increases potential cash outflows and equity dilution in a termination or CIC scenario. Investors should note the enhanced protection may aid retention during strategic discussions but could represent a modest cost if triggered.